Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers
Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers
复制标题
DOI：
10.1016/j.jsbmb.2007.03.007
复制
发表时间：
2007-05-01
影响因子：
4.1
通讯作者：
Tamaya, Teruhiko
中科院分区：
文献类型：
--
作者：
Sakaguchi, Hideki;Fujimoto, Jiro;Tamaya, Teruhiko
雌激素被认为是子宫内膜癌发生、生长和侵袭的重要调节剂。类固醇受体辅激活因子-3（SRC-3；AIB1、ACTR、RAC3、TRAM-1 和 pCIP）是核激素受体（包括雌激素受体 (ER)）共激活因子 p 160 家族的成员。据报道，SRC-3在多种癌症中过度表达。然而，SRC-3在子宫内膜癌中的表达方式尚不完全清楚。在这项研究中，我们发现 SRC-3 mRNA 表达与临床分期、子宫肌层浸润深度和去分化相关。子宫内膜癌中SRC-3 mRNA高表达的25例患者预后极差（36%），而SRC-3 mRNA低表达的15例患者的24个月生存率为96%。这些数据表明，SRC-3 可能是子宫内膜癌进展和生存的重要指标，(c) 2007 年由 Elsevier Ltd 出版。
Estrogen is recognized as a significant modifier in the development, growth and invasion of uterine endometrial cancer. Steroid receptor coactivator-3 (SRC-3; AIB1. ACTR, RAC3, TRAM-1, and pCIP) is a member of the p 160 family of coactivator for nuclear hormone receptors including estrogen receptor (ER). It is reported that SRC-3 is overexpressed in various cancers. However, SRC-3 expression manner in uterine endometrial cancer is not fully understood. In this study, we showed SRC-3 mRNA expression correlates with clinical stage, depth of myometrial invasion and dedifferentiation. The prognosis of the 25 patients with higher expression of SRC-3 mRNA in uterine endometrial cancers was extremely poor (36%), whereas the 24-month survival rate of the 15 patients with lower expression of SRC-3 mRNA was 96%. These data indicate that SRC-3 might be an important indicator of uterine endometrial cancer advancement and survival, (c) 2007 Published by Elsevier Ltd.